The prioritization of PAS-nomacopan for Geographic Atrophy and leadership changes are significant developments for Akari Therapeutics. These moves could positively influence investor perception and stock performance in the short term, given the focus on a promising therapeutic area and potential strategic improvements from new leadership.

The emphasis on Peak Bio's ADC cancer therapeutic platform as part of the merger's portfolio prioritization plan indicates a strategic focus on a high-potential area. This focus is likely to be viewed positively by investors, potentially leading to a favorable impact on Peak Bio's stock price in the short term.